Core Viewpoint - Hendi Pharmaceutical (301211.SZ) has registered its ibuprofen raw material for export to Japan, which currently contributes less than 1% of the company's total revenue, thus not significantly impacting its overall performance [1] Group 1 - The company has obtained export qualifications for ibuprofen raw materials to Japan [1] - The revenue from the export business to Japan is currently minimal, accounting for less than 1% of total revenue [1] - The registration in Japan indicates potential for future growth in international markets [1]

Group 1 - The core viewpoint of the news is that Hendi Pharmaceutical's stock performance and financial metrics indicate a mixed outlook, with a slight increase in stock price but a significant decline in revenue and net profit [1][2]. Group 2 - On November 11, Hendi Pharmaceutical's stock rose by 2.12%, with a trading volume of 612 million yuan. The financing buy-in amount was 67.87 million yuan, while the financing repayment was 74.80 million yuan, resulting in a net financing buy-in of -6.93 million yuan [1]. - As of November 11, the total margin balance for Hendi Pharmaceutical was 145 million yuan, accounting for 2.19% of its market capitalization, which is above the 60th percentile level over the past year [1]. - The company has not engaged in any short selling activities on November 11, with no shares sold or repaid, indicating a low short selling interest [1]. Group 3 - As of October 31, the number of shareholders for Hendi Pharmaceutical increased by 13.95% to 20,800, while the average circulating shares per person decreased by 12.24% to 20,040 shares [2]. - For the period from January to September 2025, Hendi Pharmaceutical reported a revenue of 319 million yuan, a year-on-year decrease of 4.52%, and a net profit attributable to shareholders of 20.93 million yuan, down 71.96% year-on-year [2]. - Since its A-share listing, Hendi Pharmaceutical has distributed a total of 378 million yuan in dividends, with 306 million yuan distributed over the past three years [2]. - As of September 30, 2025, Hong Kong Central Clearing Limited has exited the list of the top ten circulating shareholders of Hendi Pharmaceutical [2].

Company Summary - Hendi Pharmaceutical (SZ 301211) announced that as of the date of the announcement, Liu Yanchao has pledged approximately 18.79 million shares, accounting for 7.06% of his total holdings. Liu Wenchao has also pledged approximately 18.79 million shares, representing 7.06% of his holdings. Liu Sichao has pledged approximately 18.79 million shares, which is 7.06% of his holdings. Liu Tianchao has pledged approximately 16.12 million shares, making up 6.06% of his holdings [1][1][1] - For the fiscal year 2024, Hendi Pharmaceutical's revenue composition is as follows: raw materials account for 79.88%, formulations account for 19.11%, and others account for 1.01% [1][1][1] - As of the announcement, Hendi Pharmaceutical has a market capitalization of 6.6 billion yuan [1][1][1]

公司于近日收到公司实际控制人之一致行动人函告，获悉其所持有的 公司部分股份办理了质押业务，具体情况如下。 股东 名称 是否为控 股股东或 第一大股 东及其一 致行动人 本 次 质 押数量 占 其 所 持 股 份 比例 占公司 总股本 比例 是 否 为 限 售 股 （如是， 注 明 限 售类型） 是否为 补充质 押 质 押 起 始日 质 押 到 期日 质 权 人 质 押 用 途 刘妍 超 是 18,792 ,000 7.06% 4.50% 否 否 2025 年 11 月 7 日 至办理 解除质 押登记 手续之 日止 屹贲 有限 其他（投 资合作） 刘雯 超 是 18,792 ,000 7.06% 4.50% 否 否 2025 年 11 月 7 日 至办理 解除质 押登记 手续之 日止 屹贲 有限 其他（投 资合作） 刘思 超 是 18,185 ,231 6.83% 4.35% 否 否 2025 年 11 月 7 日 至办理 解除质 押登记 手续之 日止 屹贲 有限 其他（投 资合作） 一、本次股份质押基本情况 证券代码：301211 证券简称：亨迪药业 公告编号：2025-049 湖北亨迪药业股份有限公司 关于 ...

东方量化多策略混合A（006785）成立日期2019年2月22日，最新规模2878.44万。今年以来收益 32.45%，同类排名2692/8147；近一年收益24.18%，同类排名3043/8056；成立以来亏损2.63%。 东方量化多策略混合A（006785）基金经理为盛泽、王怀勋。 截至发稿，盛泽累计任职时间7年93天，现任基金资产总规模11.67亿元，任职期间最佳基金回报 132.76%， 任职期间最差基金回报-20.29%。 11月11日，亨迪药业涨5.08%，截至发稿，报16.34元/股，成交4.15亿元，换手率6.34%，总市值68.24亿 元。 资料显示，湖北亨迪药业股份有限公司位于湖北省荆门市掇刀区杨湾路122号，成立日期1995年12月29 日，上市日期2021年12月22日，公司主营业务涉及化学原料药及制剂产品的研发、生产和销售。主营业 务收入构成为：非甾体抗炎类68.06%，心血管类16.08%，其他8.86%，抗肿瘤类6.99%。 从基金十大重仓股角度 数据显示，东方基金旗下1只基金重仓亨迪药业。东方量化多策略混合A（006785）三季度持有股数1.16 万股，占基金净值比例为0.43 ...

Core Viewpoint - The flu sector has experienced a significant rally, with notable stock price increases among several pharmaceutical companies [1] Company Summaries - Special One Pharmaceutical has reached its daily limit increase in stock price [1] - Nanxin Pharmaceutical's stock has risen by over 6% [1] - Tailong Pharmaceutical, Hendi Pharmaceutical, and Zhongsheng Pharmaceutical have also seen stock price increases [1]

Core Viewpoint - The A-share market has seen a significant rise in flu-related stocks due to a noticeable increase in flu activity across China, with most provinces entering the flu epidemic period [1] Group 1: Stock Performance - Hendi Pharmaceutical has increased by over 14%, while Hualan Biological has risen by 11% [1] - Other notable performers include Peking University Pharmaceutical with a 10% increase, and Jinshi Yao with a rise of over 7% [1] - Several companies, including Teva Pharmaceutical, Erkang Pharmaceutical, and others, have also shown gains of over 5% [1] Group 2: Market Context - Recent data from the China CDC indicates that flu virus cases have surpassed other respiratory viruses, marking a significant shift in the current flu season [1] - Since mid-October, sales of related medications, such as Oseltamivir, have increased, with production running continuously [1]

Core Insights - Hendi Pharmaceutical experienced a 3.25% decline in stock price on November 6, with a trading volume of 217 million yuan [1] - The company reported a financing buy-in of 27.85 million yuan and a net financing buy of 5.98 million yuan on the same day [1] Financing Overview - As of November 6, the total financing and securities balance for Hendi Pharmaceutical was 158 million yuan, accounting for 2.70% of its market capitalization [1] - The current financing balance exceeds the 70th percentile of the past year, indicating a relatively high level [1] - No shares were sold or repaid in the securities lending market on November 6, with the securities lending balance at zero, which is below the 50th percentile of the past year [1] Company Performance - As of October 31, the number of shareholders for Hendi Pharmaceutical increased by 13.95% to 20,800, while the average circulating shares per person decreased by 12.24% to 20,040 shares [2] - For the period from January to September 2025, the company reported a revenue of 319 million yuan, a year-on-year decrease of 4.52%, and a net profit attributable to shareholders of 20.93 million yuan, down 71.96% year-on-year [2] - Since its A-share listing, Hendi Pharmaceutical has distributed a total of 378 million yuan in dividends, with 306 million yuan distributed over the past three years [2] Business Composition - Hendi Pharmaceutical's main business includes the research, production, and sales of chemical raw materials and formulations, with revenue composition as follows: non-steroidal anti-inflammatory drugs 68.06%, cardiovascular drugs 16.08%, others 8.86%, and anti-tumor drugs 6.99% [1]

（文章来源：证券日报） 证券日报网讯亨迪药业11月4日在互动平台回答投资者提问时表示，截至2025年10月31日，公司股东户 数为20838户。 ...

Core Viewpoint - Hendi Pharmaceutical, established in December 1995 and listed on the Shenzhen Stock Exchange in December 2021, is a significant player in the domestic chemical raw materials pharmaceutical sector, focusing on the R&D, production, and sales of chemical raw materials and formulations [1] Business Performance - For Q3 2025, Hendi Pharmaceutical reported revenue of 319 million yuan, ranking 38th among 47 companies in the industry, with the top company, Pro Pharmaceutical, achieving 7.764 billion yuan [2] - The net profit for the same period was 20.93 million yuan, placing the company 33rd in the industry, while the leading company, Zhejiang Pharmaceutical, reported 867 million yuan [2] Financial Ratios - As of Q3 2025, Hendi Pharmaceutical's debt-to-asset ratio was 5.92%, slightly up from 5.81% year-on-year, significantly lower than the industry average of 27.75%, indicating strong solvency [3] - The gross profit margin for Q3 2025 was 20.53%, down from 30.23% year-on-year, and below the industry average of 35.38%, suggesting a need for improvement in profitability [3] Executive Compensation - The chairman, Cheng Zhigang, received a salary of 668,300 yuan in 2024, an increase of 52,600 yuan from 2023 [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 1.53% to 17,900, while the average number of circulating A-shares held per shareholder increased by 1.55% to 23,300 [5]